THROMBOLYTIC THERAPY WITH LOCAL PERFUSIONS OF CA-7 (FIBRINOLYTIC ENZYME FROM ASPERGILLUS ORYZAE) IN THE DOG
- AN EXPERIMENTAL METHOD FOR QUANTITATIVE EVALUATION OF THROMBOLYSIS: EFFECT OF CA-7, A PROTEASE FROM ASPERGILLUS ORYZAE. Giering, John E.; Truant, Aldo P. // Angiology;Sep1966, Vol. 17 Issue 9, p661
A quantitative method is described which is based upon the insertion into the external jugular vein of a preformed, weighed blood clot formed and retracted around a special framework. The frame firmly supports and confines the clot in a fixed position within the vein without completely impeding...
- Guidelines advise on thrombotic events in urology. Tennant, Scott // Urology Times;1/1/2005, Vol. 33 Issue 1, p4
Reports on the American College of Chest Physicians' "Guidelines on Antithrombotic and Thrombolytic Therapy". Risk factors for venous thromboembolism in urologic surgery patients; Mechanical thromboprophylaxis modalities; Comparison between mechanical methods of prophylaxis and anticoagulant...
- CORONARY ARTERIAL AND OTHER INTRAVASCULAR THROMBOSES TREATED WITH FIBRINOLYSIN. Mazel, M. S.; Bolton, Houck E.; Stern, Joel R.; Riera, Rogelio; Cabral, Hector // Angiology;Feb1963, Vol. 14 Issue 2, p88
Investigates the efficacy of fibrinolytic agents for the treatment of intravascular thromboses. Accomplishment of cerebral embolization by cannulation of the carotid artery; Doubts on the actual amount of fibrinolysin which the brain can tolerate by perfusion of a carotid artery; Safety profile...
- SYSTEMIC TOXICITY OF CA-7 (FIBRINOLYTIC ENZYME FROM ASPERGILLUS ORYZAE) IN THE DOG. Roschlau, Walter H. E. // Angiology;Nov1966, Vol. 17 Issue 11, p882
The toxic effects of systemic thrombolytic doses of CA-7 (fibrinolytic enzyme from Aspergillus oryzae) in 36 dogs are summarized. The more important of these are transient hypocoagulability of the blood, transient hypotension, reversible hemoconcentration, reversible liver involvement and...
- Differential Regulation of Matrix Metalloproteinase-9 and Tissue Plasminogen Activator Activity by the Cyclic-AMP System in Lipopolysaccharide-stimulated Rat Primary Astrocytes. Soon Lee; Hee Kim; Woo Lee; So Joo; Se-Jin Jeon; Ji Kim; Seol-Heui Han; Jongmin Lee; Seung Park; Jae Cheong; Won-Ki Kim; Kwang Ko; Chan Shin // Neurochemical Research;Nov2008, Vol. 33 Issue 11, p2324
AbstractÂ Â We investigated the effect of the cAMP system on lipopolysaccharide (LPS)-induced changes in the activity of matrix metalloproteinases (MMPs) and tissue plasminogen activator (tPA) in rat primary astrocytes. LPS stimulation increased MMP-9 and decreased tPA activity in rat...
- Plasminogen-related. // Encyclopedic Reference of Cancer;2001, p701
A definition of the term "plasminogen-related protein" is presented. It refers to a protein that shares structural similarity and evolutionary relationship with plasminogen.
- A QUANTITATIVE METHOD FOR THE STUDY OF THROMBOLYSIS. Boyles, Paul W.; Meyer, William H. // Angiology;Jul1964, Vol. 15 Issue 7, p326
An apparatus is described combining the advantages of in vivo and in vitro methods for the study of clot lysis. This technique permits direct observation of a standard clot in the presence of a dynamic circulation.
- Multicenter Trials of Treatment for Empyema – After All These Years. Heffner, John E. // New England Journal of Medicine;3/3/2005, Vol. 352 Issue 9, p926
The article focuses on the lack of evidence concerning treatment for empyema. As stated, with the absence of high-quality trials, suggestions for managing pleural infections have relied on pathophysiological observations, small studies, and expert opinion. In this context, a multicenter study...
- Thrombolytic Drugs in Acute Myocardial Infarction. Iqbal, Omer; Messmore, Harry; Hoppensteadt, Debra; Fareed, Jawed; Wehrmacher, William // Clinical & Applied Thrombosis/Hemostasis;Jan2000, Vol. 6 Issue 1, p1
Focuses on the role of thrombolytic drugs in the management of patients with acute myocardial infarction. Discussion on the timing and survival benefit of using thrombolytic drugs; Selection criteria for lytic therapy; Description of the three generations of thrombolytic agents.